OTCMKTS:IMUCD ImmunoCellular Therapeutics (IMUCD) Stock Price, News & Analysis → Claim Your FREE 'AI Income Playbook' Now! (From The Oxford Club) (Ad) Free IMUCD Stock Alerts $0.19 0.00 (0.00%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$0.12▼$0.1950-Day Range$0.13▼$0.2552-Week Range$0.16▼$0.51Volume321 shsAverage Volume6,605 shsMarket Capitalization$796,100.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartStock AnalysisChart Get ImmunoCellular Therapeutics alerts: Email Address Ad The Oxford ClubAmerica's #1 AI Dividend Stock RevealedIncome expert Marc Lichtenfeld has a special gift reserved just for you... It's his brand-new "AI Income Playbook" - and it's yours FREE!Click here now to claim your FREE copy of Marc's AI playbook. About ImmunoCellular TherapeuticsImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers. The company's lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. Its pipeline also includes ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. The company was founded on January 30, 2006 and is headquartered in Calabasas, CA.Read More IMUCD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMUCD Stock News HeadlinesJune 23, 2023 | finance.yahoo.comRVVTF - Revive Therapeutics Ltd.April 16, 2023 | thestreet.comBlame for Northwest Bio Collapse Lies With CEO, Not With Mythical 'Wolfpack'See More Headlines Receive IMUCD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmunoCellular Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolOTCMKTS:IMUCD CUSIPN/A CIKN/A Webwww.imuc.com Phone(818) 264-2300FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares4,190,000Free FloatN/AMarket Cap$796,100.00 OptionableNot Optionable Beta1.63 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Gary S. Titus CPA (Age 60)Independent Chairman & Corp. Sec. Comp: $63kMr. Sanford J. Hillsberg (Age 71)Co-Founder Dr. John S. Yu (Age 56)Founder & Director Key CompetitorsBio-PathNASDAQ:BPTHTonix PharmaceuticalsNASDAQ:TNXPPetros PharmaceuticalsNASDAQ:PTPIGeoVax LabsNASDAQ:GOVXOnconetixNASDAQ:ONCOView All Competitors IMUCD Stock Analysis - Frequently Asked Questions How have IMUCD shares performed in 2024? ImmunoCellular Therapeutics' stock was trading at $0.2320 at the beginning of 2024. Since then, IMUCD shares have decreased by 18.1% and is now trading at $0.19. View the best growth stocks for 2024 here. How do I buy shares of ImmunoCellular Therapeutics? Shares of IMUCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:IMUCD) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredDon't Buy These Big-Name Cryptos!Since Google's IPO in 2004 shares have climbed a whopping 6,000%! Unless you're a longtime holder of Bitcoin, ...Manward Press | Sponsored"Second Wave" Could send AI stock Soaringhis "second wave" of AI gains has already given some early investors the chance to see gains of 133% in 15 day...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunoCellular Therapeutics, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunoCellular Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.